Literature DB >> 33941576

Th17 Cells Provide Mucosal Protection against Gastric Trypanosoma cruzi Infection.

Catherine W Cai1,2, Christopher S Eickhoff1, Krystal A Meza1, Jennifer R Blase1,2, Rebecca E Audette1, David H Chan1, Kevin A Bockerstett2, Richard J DiPaolo2, Daniel F Hoft1,2.   

Abstract

Trypanosoma cruzi is the intracellular parasite of Chagas disease, a chronic condition characterized by cardiac and gastrointestinal morbidity. Protective immunity requires CD4+ T cells, and Th1 cells and gamma interferon (IFN-γ) are important players in host defense. More recently, Th17 cells and interleukin 17A (IL-17A) have been shown to exert protective functions in systemic T. cruzi infection. However, it remains unclear whether Th17 cells and IL-17A protect in the mucosa, the initial site of parasite invasion in many human cases. We found that IL-17RA knockout (KO) mice are highly susceptible to orogastric infection, indicating an important function for this cytokine in mucosal immunity to T. cruzi. To investigate the specific role of Th17 cells for mucosal immunity, we reconstituted RAG1 KO mice with T. cruzi-specific T cell receptor transgenic Th17 cells prior to orogastric T. cruzi challenges. We found that Th17 cells provided protection against gastric mucosal T. cruzi infection, indicated by significantly lower stomach parasite burdens. In vitro macrophage infection assays revealed that protection by Th17 cells is reduced with IL-17A neutralization or reversed by loss of macrophage NADPH oxidase activity. Consistently with this, mice lacking functional NADPH oxidase were not protected by Th17 cell transfer. These data are the first report that Th17 cells protect against mucosal T. cruzi infection and identify a novel protective mechanism involving the induction of NADPH oxidase activity by IL-17A. These studies provide important insights for Chagas vaccine development and, more broadly, increase our understanding of the diverse roles of Th17 cells in host defense.

Entities:  

Keywords:  Chagas disease; IL-17; IL-17A; NADPH oxidase; Th17 cells; Trypanosoma cruzi; neglected tropical diseases; parasitology; reactive oxygen species

Mesh:

Substances:

Year:  2021        PMID: 33941576      PMCID: PMC8208511          DOI: 10.1128/IAI.00738-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.

Authors:  D F Hoft; C S Eickhoff
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Increased susceptibility of Fas ligand-deficient gld mice to Trypanosoma cruzi infection due to a Th2-biased host immune response.

Authors:  M F Lopes; M P Nunes; A Henriques-Pons; N Giese; H C Morse; W F Davidson; T C Araújo-Jorge; G A DosReis
Journal:  Eur J Immunol       Date:  1999-01       Impact factor: 5.532

Review 3.  Chagas disease.

Authors:  Anis Rassi; Anis Rassi; José Antonio Marin-Neto
Journal:  Lancet       Date:  2010-04-17       Impact factor: 79.321

4.  Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease.

Authors:  R L Tarleton; J Sun; L Zhang; M Postan
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  IL-17 is necessary for host protection against acute-phase Trypanosoma cruzi infection.

Authors:  Yoshiyuki Miyazaki; Shinjiro Hamano; Seng Wang; Yohei Shimanoe; Yoichiro Iwakura; Hiroki Yoshida
Journal:  J Immunol       Date:  2010-06-18       Impact factor: 5.422

6.  Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease.

Authors:  R L Tarleton; M J Grusby; M Postan; L H Glimcher
Journal:  Int Immunol       Date:  1996-01       Impact factor: 4.823

7.  Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi.

Authors:  D F Hoft; A R Schnapp; C S Eickhoff; S T Roodman
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

8.  Tolerance of benznidazole in treatment of Chagas' disease in adults.

Authors:  María-Jesús Pinazo; José Muñoz; Elizabeth Posada; Paulo López-Chejade; Montserrat Gállego; Edgar Ayala; Elena del Cacho; Dolors Soy; Joaquim Gascon
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

9.  Chagas disease in dogs from endemic areas of Costa Rica.

Authors:  Victor M Montenegro; Maurico Jimenez; J C Pinto Dias; Rodrigo Zeledon
Journal:  Mem Inst Oswaldo Cruz       Date:  2002-06       Impact factor: 2.743

10.  IL-17RA signaling reduces inflammation and mortality during Trypanosoma cruzi infection by recruiting suppressive IL-10-producing neutrophils.

Authors:  Jimena Tosello Boari; María Carolina Amezcua Vesely; Daniela Andrea Bermejo; Maria Cecilia Ramello; Carolina Lucía Montes; Hugo Cejas; Adriana Gruppi; Eva Virginia Acosta Rodríguez
Journal:  PLoS Pathog       Date:  2012-04-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.